Betrixaban (Bevyxxa)


Indications for Prior Authorization:

  • Indicated for the prophylaxis of Venous Thromboembolism (VTE) in adult patients hospitalized for an acute medical illness who are at risk for thromboembolic complications due to moderate to severe restricted mobility and other risk factors for VTE

Patients must meet the following criteria for the indication(s) above:

  • Patient is hospitalized for an acute medical illness and at risk for thromboembolic complications due to severe restricted mobility or other risk factors for VTE, AND
  • Patient is at least 18 years of age or older, AND
  • Patient does not have active pathological bleeding, AND
  • Patient is not currently receiving neuraxial anesthesia or undergoing spinal puncture, AND
  • Patient has not received up to 42 days of Bevyxxa therapy, AND
  • Patient has tried and failed or contraindication to a FactorXa inhibitor (Eliquis or Xarelto)


  • Single dose of 160 mg, followed by 80 mg once daily
  • Recommended duration of treatment is 35-42 days
  • Severe renal impairment (CrCl  15 to < 30 mL/min) OR use with P-gp inhibitors:
    • Single dose of 80 mg, followed by 40 mg once daily
    • Recommended treatment duration is 35-42 days
  • Patients with epidural catheters:
    • Do not remove epidural catheter earlier than 72 hours after the last administration of Bevyxxa
    • Do not administer the next Bevyxxa dose earlier than 5 hours after the removal of the catheter
    • If tramatic puncture occurs, delay administration of Bevyxxa for 72 hours 


  • One treatment course (35-42 days)
WHA is closely monitoring the Coronavirus Disease 2019 (COVID-19). Learn more about COVID-19.